Visual Intelligence™ (VI®) removes diagnosis uncertainty empowering clinicians.
“This is the most exciting development I have seen since I worked on the introduction of CT.” Dr. Frank Vogel, M.D., Pediatric Radiologist
“Exceptional results never obtained by any other National Cancer Institute study.”
Most natural objects — and that includes human beings — are composed of many different types of fractals woven into each other, each with parts which have different fractal
Imago’s, Visual Intelligence fractal approach has the potential to allow physicians and scientists to predict clinical outcomes, classification between normal and pathological states, and ultimately, identifying and diagnosing medical conditions.
“IMAGO’S platform fits seamlessly by design into existing DICOM and HIPAA compliant medical imaging protocols and reveals transformative diagnostic insights.” Thomas E. Ramsay, Founder and CEO, Imago Systems
*As we continue to develop Imago’s Visual Intelligence™ IP, we will submit a 510(k) application for a single-source version of its technology for an accredited review under the U.S. Food and Drug Administration’s (the “FDA”) 510(k) Third Party Review Program in early 2022.